Clinical trialNCT06947083RecruitingPhase 2Interventional

Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment39Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Melissa Alsina, MD
Moffitt Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moffitt Cancer Center
Tampa, Florida, United States
Ariel Grajales-Cruz, MDBrandon Blue, MDCiara Freeman, MD, MSc, PhDDoris Hansen, MDFrederick Locke, MDHien Liu, MDKenneth Shain, MD, PhDMelissa Alsina, MD →Omar Castaneda Puglianini, MDRachid Baz, MDTaiga Nishihori, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elranatamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 May 2025
Primary completion: 30 Apr 2029
Completion: 30 Apr 2029
Last update posted: 3 Dec 2025
Registered enrollment: 39
Registry id: NCT06947083

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.